宋相容 - 四川大学 - 生物治疗国家重点实验室

个人简介

【教育经历】 2017年哈佛大学医学院Brigham and Women’s Hospital，纳米医学访问学者 2016年哈佛大学医学院Dana-Farber Cancer Institute，免疫学访问学者 2015年四川大学生物治疗国家重点实验室，生物学博士后 2003–2008 四川大学华西药学院，药剂学博士 1999–2003 四川大学华西药学院，药学学士【科研与学术工作经历】 2015-至今：四川大学，生物治疗国家重点实验室，研究员 2010-2015：四川大学，生物治疗国家重点实验室，副研究员 2008-2010：四川大学，生物治疗国家重点实验室，助理研究员 2014：第十一批四川省学术和技术带头人后备人选 2013 -至今：四川大学，生物治疗国家重点实验室，破格选为博士生导师 2011：四川大学，生物治疗国家重点实验室，评为“优秀青年骨干教师” 2009：四川大学，生物治疗国家重点实验室，破格选为硕士生导师

研究领域

基因药物、多肽药物、化学药物、中药及天然药物有效部位及有效成分的常规制剂及靶向新制剂，具体包括片剂、胶囊、乳膏、混悬剂、纳米混悬剂、包合物、固体分散体、固体脂质纳米粒、脂质体、纳米粒、胶束，原位凝胶、各种靶向制剂（肺靶向、肝靶向、脑靶向、肿瘤靶向等），等等。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

[52] Macrophage foam cell-targeting immunization attenuates atherosclerosis. Front Immunol. 2018 (SCI, IF 5.511, *通讯) [51] Folate-modified liposomes loaded with telmisartan enhance anti-atherosclerotic potency for advanced atherosclerosis in ApoE-/- mice. J Biomed Nanotechnol. 2018 (SCI, IF 5.068, *通讯) [50] TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma. Int J Pharm, 2018, 553: 21-28 (SCI, IF 4.06, *通讯) [49] Optimization of the mannose-cholesterol conjugates for enhanced mRNA targeting delivery to dendritic cells. Front Pharmacol. 2018, 9:980. (SCI, IF 4.04, *通讯) [48] Nanoliposome-encapsulated brinzolamide-hydropropyl-β-cyclodextrin inclusion complex: A potential therapeutic ocular drug-delivery system. Front Pharmacol. 2018, 9:91 (SCI, IF 4.04, *通讯) [47] eIF3i activity is critical for endothelial cells in tumor induced angiogenesis through regulating VEGFR and ERK translation. Oncotarget. 2017, 8(12):19968-19979. (SCI, IF 5.17, *通讯) [46] Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1pathway in hypertensive nephropathy. J Hypertens. 2017, 35(7):1442-1456 (SCI, IF 4.72, *通讯) [45] Enhanced and extended anti-hypertensive effect of VP5 nanoparticles. Int J Mol Sci. 2016, 17(12), 1977 (SCI, IF 3.26, *通讯) [44] Combined tumor- and neovascular-“dual targeting” gene/chemo-therapy suppresses tumor growth and angiogenesis. ACS Appl Mater Inter. 2016, 8 (39): 25753–25769 (SCI, IF 7.15, *通讯) [43] Promising nanocarriers for PEDF gene targeting delivery to cervical cancer cells mediated by the over-expressing FRα. Sci Rep. 6:32427 (2016) (SCI, IF 5.23, *通讯) [42] Simultaneous determination of telmisartan and pitavastain in rat plasma by UPLC-MS/MS: Application to pharmacokinetic interaction study. J Pharm Biomed Anal. 131:373-379 (2016) (SCI, IF 3.17, * 通讯) [41] Pigment epithelial-derived factor gene loaded novel CPPC nanoparticles promoted tumor suppression by systemic administration. Int J Nanomed. 11: 743 (2016)(SCI, IF 4.383, *通讯) [40] Polymeric nanomedicine for combined geneemo-therapy elicits enhanced tumor suppression. Mol Pharmaceut. 13: 663 (2016) (SCI, IF 4.384, *通讯) [39] 不同干燥方法对五龙颗粒浸膏品质的影响. 中国新药杂志. 24: 1911 (2015) (中文核心, * 通讯) [38] 载姜黄素甲氧基聚乙二醇-聚谷氨酸-胆固醇共聚物纳米粒的制备及表征. 中国新药杂志. 24: 2251 (2015) (中文核心, * 通讯) [37] Dunkin Hartley白化豚鼠和Hartley花色豚鼠高脂造模以及降脂药效学的比较. 中国比较医学杂志. 25:56 (2015) (中文核心, * 通讯) [36] Liposomes as a novel ocular delivery system for brinzolamide: In vitro and in vivo studies. AAPS PharmSciTech. (2015) (SCI, IF 1.64, *通讯) [35] Effect of telmisartan on the therapeutic efficacy of pitavastatin in high-fat diet induced dyslipidemic guinea pigs. Eur J Pharmacol. 762: 364 (2015) (SCI, IF 2.532, *通讯) [34]α, ω-cholesterol-functionalized low molecular weight polyethylene glycol as a novel modifier of cationic liposomes for gene delivery. Int J Mol Sci. 5: 20339 (2014) (SCI, IF 2.451, *通讯)